No Detail Found!

Beta-Adrenergic Blockers' Supportive and Adverse Role in Hypertension: A Review of Three Generations

Author(s)
Zakir Khan Institute of Health Sciences, Faculty of Medicine, Department of Pharmacology, Cukurova University, Adana, Turkey,
Elif Demirtaş Institute of Health Sciences, Faculty of Medicine, Department of Pharmacology, Cukurova University, Adana, Turkey
Olcay Kıroğlu Institute of Health Sciences, Faculty of Medicine, Department of Pharmacology, Cukurova University, Adana, Turkey
Yusuf Karataş Institute of Health Sciences, Faculty of Medicine, Department of Pharmacology, Cukurova University, Adana, Turkey; Pharmacovigilance specialist, Balcali hospital, Faculty of Medicines, Cukurova University, Adana, Turkey.
Abstract
Hypertension causes significant mortality and morbidity around the world. The ß-adrenergic blockers are one of the most commonly prescribed hypertension medications. Several ß-adrenergic blockers with different pharmacological qualities have been developed, which may be grouped into three generations based on the differences in pharmacological properties. In this narrative review, we addressed evidence-based literature about the role of various types of ß-blockers and related adverse drug reactions (ADRs) in hypertension. PubMed, Scopus, Google Scholar, and MEDLINE are used for articles search. The title was examined first, followed by the abstract, and then the entire study. We concluded that the first-generation ß-blockers are non-selective and used as antihypertensive however, not recommended for diabetic, asthmatic, and chronic obstructive pulmonary disease patients. The second-generation ß-blockers are ß1 receptor-selective which are the effective pharmacological option for the treatment of hypertension, with a lower risk of adverse effects associated with antagonism of ß 2-receptor. Third-generation ß-blockers showed improved effects on patients as compared to the previous two generations. This class of ß-blockers (labetalol, carvedilol, and nebivolol) has vasodilatory abilities and has an extra beneficial influence with fewer ADRs. However, the effectiveness and benefit of ß-blockers as first-line therapy for hypertension is still controversial. As a result, further accurate screenings, as well as large randomized control clinical trials (RCTs), are needed to investigate the role of all ß-blockers in hypertension.
Publication Details
Page(s) 63-71
Published Journal: Pakistan Journal of Medicine and Dentistry, Volume: 11, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Hypertension, Blood pressure, Literature review, Beta-Adrenergic Blockers
0

Citations

0

Downloads

35

Views